{{Rsnum
|rsid=11211503
|Gene=STIL
|Chromosome=1
|position=47277517
|Orientation=plus
|GMAF=0.06566
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=STIL
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 0.0 | 0.0 | 100.0
| HCB | 5.2 | 35.6 | 59.3
| JPT | 1.8 | 20.4 | 77.9
| YRI | 0.0 | 4.1 | 95.9
| ASW | 0.0 | 3.5 | 96.5
| CHB | 5.2 | 35.6 | 59.3
| CHD | 4.6 | 31.5 | 63.9
| GIH | 0.0 | 23.8 | 76.2
| LWK | 0.0 | 16.5 | 83.5
| MEX | 0.0 | 7.0 | 93.0
| MKK | 1.9 | 14.9 | 83.1
| TSI | 0.0 | 1.0 | 99.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs11211503
|Name_s=
|Gene_s=STIL
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: A, MAF= 0.02, combined P value= 3.13E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470230
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11211503
|overall_frequency_n=10
|overall_frequency_d=128
|overall_frequency=0.078125
|n_genomes=8
|n_genomes_annotated=0
|n_haplomes=9
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}